---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021281"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T03:55:59.953258+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biodesix Q1 revenue $9.1M (+38% YoY); core lung diagnostics up 86% to $8.6M

## Summary
- Total revenue $9.1M, +38% YoY; core lung diagnostic revenue $8.6M, +86% YoY.
- Net loss $18.7M ($0.24 per share); operating expenses $22.3M up 25% YoY.
- Gross margin improved to 65% from 51% due to shift from lower-margin COVID-19 tests.
- COVID-19 testing revenue down 99% YoY; company discontinues commercial COVID-19 testing.
- Reaffirmed 2023 total revenue guidance $52M-$55M; cash $25.3M as of March 31.

## SEC filing metadata
- accession: 0000950170-23-021281
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000095017023021281/0000950170-23-021281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000095017023021281/bdsx-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021281
- JSON: https://secwatch.observer/filing/0000950170-23-021281.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021281.txt

## Key facts
- Earnings Releases
  BIODESIX INC reported the first quarter ended March 31, 2023 results: revenue $9.1 million, net income $18.7 million, EPS $0.24. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $9.1 million
  - Net income: $18.7 million
  - EPS: $0.24
  - Guidance: reaffirmed
  - Result: reported results
  source text: First Quarter 2023 Financial Results For the three-month period ended March 31, 2023, as compared to the same period of 2022 (where applicable): • Total revenue of $9.1 million, an increase of 38%, driven primarily by strong year-over-year growth in core lung diagnostics: o Core lung diagnostic revenue of $8.6 million reflected a year-over-year increase of 86% driven primarily by the continued adoption of Nodify Lung® nodule management tests; o BioPharma Services revenue of $0.4 million decreased 55% year-over-year. Timelines for existing and new agreements continue to be impacted by delayed enrollment in clinical trials; entered the second quarter of 2023 with continued strong dollars under contract; o COVID-19 testing revenue decreased by 99% year-over-year, and consistent with our revenue guidance. In connection with the expected expiration of the Public Health Emergency declaration, the Company will no longer provide COVID-19 diagnostic testing services commercially; • First quarte
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439725/000095017023021281/0000950170-23-021281-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.